Patent royalties are recurring payments made to a patent holder by a licensee in exchange for the right to use, manufacture, sell, or distribute a patented invention. These payments typically continue for the life of the patent (usually 20 years from filing) or until the license agreement expires. Royalty rates vary widely—from 2-3% in mature industries to 10-15% in emerging tech sectors—and can significantly impact a company's profitability and valuation.
How It Works
When a company licenses a patented technology, it negotiates terms with the patent owner. The licensee agrees to pay either a lump sum upfront, milestone payments, or ongoing royalties based on revenue or unit sales. Most agreements combine these—an initial license fee plus a percentage of revenue or per-unit royalty. These payments flow directly to the patent owner, reducing the licensee's net income and cash available for operations and growth.
Why It Matters for Investors
Understanding patent royalty obligations is critical for due diligence. A startup paying 8% royalties on gross revenue faces significantly different unit economics than one with a 2% obligation. High royalty rates can compress margins, limit scaling potential, and reduce returns. Conversely, if you're investing in a company that owns valuable patents generating royalty income from licensees, that's a predictable revenue stream that increases enterprise value. Always review licensing agreements for renewal terms, escalation clauses, and territorial restrictions that could affect future growth.
Example
A biotech startup licensed a drug compound patent from a university. The agreement requires a 4% royalty on net sales, plus a $500,000 annual minimum payment. If the company projects $50 million in annual revenue within five years, it will owe $2 million annually in royalties—a real cost that must be factored into your return projections. If the company owns its own core patents instead, that $2 million stays on the balance sheet, significantly improving valuation multiples and investor IRR.
Key Takeaways
- Patent royalties are ongoing costs that reduce profitability and should be modeled carefully in financial projections
- Royalty rates vary by industry and technology maturity; benchmark against comparable deals in the sector
- Review license agreements for termination clauses, rate escalations, and exclusivity terms that affect competitive positioning
- Owning patents (rather than licensing them) creates a strategic advantage and higher valuations—a key differentiator in tech and biotech investing